Cytocompatibility Evaluation of a Novel Series of PEG-Functionalized Lactide-Caprolactone Copolymer Biomaterials for Cardiovascular Applications.
bioresorbable
cytocompatibility
poly-L-lactide
poly-ε-caprolactone
polyethylene glycol
Journal
Frontiers in bioengineering and biotechnology
ISSN: 2296-4185
Titre abrégé: Front Bioeng Biotechnol
Pays: Switzerland
ID NLM: 101632513
Informations de publication
Date de publication:
2020
2020
Historique:
received:
21
04
2020
accepted:
29
07
2020
entrez:
9
9
2020
pubmed:
10
9
2020
medline:
10
9
2020
Statut:
epublish
Résumé
Although the use of bioresorbable materials in stent production is thought to improve long-term safety compared to their durable counterparts, a recent FDA report on the 2-year follow-up of the first FDA-approved bioresorbable vascular stent showed an increased occurrence of major adverse cardiac events and thrombosis in comparison to the metallic control. In order to overcome the issues of first generation bioresorbable polymers, a series of polyethylene glycol-functionalized poly-L-lactide-co-ε-caprolactone copolymers with varying lactide-to-caprolactone content is developed using a novel one-step PEG-functionalization and copolymerization strategy. This approach represents a new facile way toward surface enhancement for cellular interaction, which is shown by screening these materials regarding their cyto- and hemocompatibility in terms of cytotoxicity, hemolysis, platelet adhesion, leucocyte activation and endothelial cell adhesion. By varying the lactide-to-caprolactone polymer composition, it is possible to gradually affect endothelial and platelet adhesion which allows fine-tuning of the biological response based on polymer chemistry. All polymers developed were non-cytotoxic, had acceptable leucocyte activation levels and presented non-hemolytic (<2% hemolysis rate) behavior except for PLCL-PEG 55:45 which presented hemolysis rate of 2.5% ± 0.5. Water contact angles were reduced in the polymers containing PEG functionalization (PLLA-PEG: 69.8° ± 2.3, PCL-PEG: 61.2° ± 7.5) versus those without (PLLA: 79.5° ± 3.2, PCL: 76.4° ± 10.2) while the materials PCL-PEG550, PLCL-PEG550 90:10 and PLCL-PEG550 70:30 demonstrated best endothelial cell adhesion. PLLA-PEG550 and PLCL-PEG550 70:30 presented as best candidates for cardiovascular implant use from a cytocompatibility perspective across the spectrum of testing completed. Altogether, these polymers are excellent innovative materials suited for an application in stent manufacture due to the ease in translation of this one-step synthesis strategy to device production and their excellent
Identifiants
pubmed: 32903548
doi: 10.3389/fbioe.2020.00991
pmc: PMC7438451
doi:
Types de publication
Journal Article
Langues
eng
Pagination
991Informations de copyright
Copyright © 2020 Pacharra, McMahon, Duffy, Basnett, Yu, Seisel, Stervbo, Babel, Roy, Viebahn, Wang and Salber.
Références
Scientifica (Cairo). 2013;2013:392584
pubmed: 24278774
Tissue Eng. 2003 Feb;9(1):71-84
pubmed: 12625956
Biomaterials. 2008 Jan;29(3):302-13
pubmed: 17935776
Curr Treat Options Cardiovasc Med. 2015 Aug;17(8):393
pubmed: 26154294
Biomaterials. 2004 Dec;25(28):5939-46
pubmed: 15183608
Biotechnol Adv. 2012 Jan-Feb;30(1):321-8
pubmed: 21756992
J Biomed Mater Res A. 2007 Feb;80(2):381-90
pubmed: 17001645
Macromol Biosci. 2004 Sep 16;4(9):835-64
pubmed: 15468294
Chem Phys Lipids. 1993 Sep;64(1-3):263-74
pubmed: 8242838
Br J Anaesth. 2004 Jul;93(1):105-13
pubmed: 15121728
Biomaterials. 2008 Jul;29(20):2941-53
pubmed: 18440630
Biotechnol Lett. 2008 Dec;30(12):2085-90
pubmed: 18661107
Biomacromolecules. 2015 Jun 8;16(6):1682-94
pubmed: 25877934
J Colloid Interface Sci. 2012 Feb 15;368(1):636-47
pubmed: 22172691
J Biomed Mater Res B Appl Biomater. 2010 Apr;93(1):59-64
pubmed: 20186802
J Biomed Mater Res A. 2014 Feb;102(2):588-609
pubmed: 23520056
ACS Appl Mater Interfaces. 2016 Oct 12;8(40):26648-26656
pubmed: 27636330
J Mech Behav Biomed Mater. 2015 Aug;48:153-163
pubmed: 25933171
J Invasive Cardiol. 2006 Feb;18(2):70-4
pubmed: 16446520
Biointerphases. 2016 Jun 12;11(2):029802
pubmed: 26872581
Biomacromolecules. 2008 Nov;9(11):2969-79
pubmed: 18831592
J Control Release. 2012 Jul 20;161(2):703-12
pubmed: 22366546
Int J Nanomedicine. 2010 Mar 09;5:129-36
pubmed: 20309399
Br Med Bull. 2013;106:193-211
pubmed: 23532779
Biomaterials. 2010 Jan;31(3):532-40
pubmed: 19819014
Stem Cells Int. 2016;2016:5309484
pubmed: 26839562
Drug Metab Dispos. 2007 Jan;35(1):9-16
pubmed: 17020954
Tex Heart Inst J. 2010;37(3):343-6
pubmed: 20548819
Biomaterials. 1993 Jul;14(9):657-64
pubmed: 8399962
BMC Cardiovasc Disord. 2016 Feb 12;16:38
pubmed: 26868826
Biochem Pharmacol. 2012 Mar 15;83(6):695-704
pubmed: 22100985
Acta Biomater. 2013 Nov;9(10):8678-89
pubmed: 23467041
J Control Release. 2014 Nov 10;193:188-201
pubmed: 24845127
EuroIntervention. 2016 Mar;11(12):1389-99
pubmed: 26151954
Biomaterials. 2009 Oct;30(29):5341-51
pubmed: 19577800
Expert Opin Drug Deliv. 2016 Oct;13(10):1489-99
pubmed: 27550021
J Am Coll Cardiol. 2010 Aug 31;56(10 Suppl):S1-42
pubmed: 20797502
J Biomed Mater Res B Appl Biomater. 2019 Apr;107(3):624-634
pubmed: 30091510
Tissue Eng Part B Rev. 2013 Aug;19(4):292-307
pubmed: 23252992
Chem Soc Rev. 2015 Aug 7;44(15):5680-742
pubmed: 26023741
Biomaterials. 2009 Sep;30(27):4447-56
pubmed: 19535136
J Biomed Mater Res. 2000 Sep 15;51(4):694-702
pubmed: 10880118
JACC Cardiovasc Interv. 2014 Jan;7(1):89-99
pubmed: 24139932
J Mech Behav Biomed Mater. 2012 May;9:100-12
pubmed: 22498288
Circ Cardiovasc Interv. 2009 Jun;2(3):255-60
pubmed: 20031723
Nat Biotechnol. 2009 Dec;27(12):1135-7
pubmed: 20010596